

## PRESSURE BIOSCIENCES INC.

14 Norfolk Avenue  
South Easton, MA 02375  
(T) 508-230-1828  
(F) 508-230-1829  
[info@pressurebiosciences.com](mailto:info@pressurebiosciences.com)

Mr. Richard T. Schumacher, CEO, President  
Dr. Edmund Y. Ting, SVP of Engineering  
Dr. Alexander V. Lazarev, Chief Science Officer  
Mr. Daniel J. Shea, CPA, Senior Advisor - Finance  
Dr. Nate Lawrence, Senior Advisor - Operations

---

## STOCK OVERVIEW

Symbol:	PBIO	Recent Close:	\$2.30 as of 1/21/21)
Exchange:	OTCQB	52-Week Range:	\$1.19 - \$4.49
Shares OS <sup>1</sup> :	3.8M (17.4M FD)	Market Capitalization <sup>2</sup> :	\$8.8M (\$40M FD)
Float:	~2.6M	Fiscal Year End:	December 31
Revenue (FY 2019)	\$1.8M	Transfer Agent:	Computershare

---

## COMPANY OVERVIEW

**Pressure BioSciences, Inc. (OTCQB: PBIO)** is a leader in the development & sale of innovative, enabling, pressure-based platform solutions for the worldwide life sciences and other industries. Our products/services are based on three patented, pressure-enhanced platforms: (i) Pressure Cycling Technology (“PCT”), (ii) BaroFold Technology (“BaroFold”), and (iii) Ultra Shear Technology (“UST”).

**The PCT Platform** uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., critical steps performed by hundreds of thousands of scientists worldwide, such as cell lysis and biomolecule extraction). Our primary focus is in making our recently released, GMP-compliant, next generation PCT-based Barocycler EXTREME instrument available globally to biopharmaceutical drug manufacturers for use in the design, development, characterization, and quality control of biotherapeutic drugs. The PCT Platform is also used in such areas as biomarker and target discovery, soil & plant biology, anti-bioterror, and forensics. We currently have over 300 PCT instrument systems placed in approximately 200 academic, government, pharmaceutical, and biotech research laboratories worldwide. There are over 120 independent publications highlighting the advantages of using the PCT Platform in scientific research studies, many from worldwide key opinion leaders. The PCT Platform is offered through the Company’s Research Products & Services Group.

**The BaroFold Platform** can be used to significantly impact and improve the quality of protein therapeutics. It employs high pressure for the disaggregation and controlled refolding of proteins to their native structures at yields and efficiencies not achievable using existing technologies. The BaroFold Platform has been shown to remove protein aggregates in biotherapeutic drug manufacturing, thereby improving product efficacy and safety for both new-drug entities and biosimilar products. The BaroFold Platform can help companies create novel protein therapeutics, accelerate therapeutic protein development, manufacture follow-on biologics, and enable life-cycle management of protein therapeutics. It is scalable and practical for standard manufacturing processes. This unique technology platform can help protein-based biopharmaceutical companies create and manufacture high quality, novel protein therapeutics and lower the cost of existing formulations. Research and manufacturing licenses are available.

**The UST Platform** is based on the use of intense shear forces from ultra-high pressure (greater than 20,000 psi) valve discharge. UST has been shown to turn hydrophobic extracts into stable, water-soluble formulations on a small, laboratory scale. The UST Platform offers the potential to produce stable nanoemulsions of oil-like products in water. Such formulations could potentially have enormous success in many markets, including inks, paints, and cosmetics, as well as in pharmaceuticals and nutraceuticals, such as medically important plant oil extracts, i.e., making CBD-enriched plant oil water soluble. We believe that UST has the potential to play a significant role in a number of commercially important areas, including (i) the creation of stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water), and (ii) the preparation of higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies, e.g., dairy products. The UST Platform is currently being developed for commercialization.

---

1. Shares Outstanding (as of September 30, 2020) – includes approximately 3.8M common shares, 1.3M common share equivalents from the Company's outstanding stock options, 8.4M common share equivalents from Preferred Stock Series D, G, H, J, K, AA, and 3.9M from convertible loans on an as-converted basis.  
2. Fully Diluted Market Capitalization is calculated using Common Stock OS and Common Equivalent Shares OS on a Fully Diluted basis.

## INVESTMENT HIGHLIGHTS

- PBI has Proven Core Technology with Multiple Applications (Over 300 Pressure Systems Installed Globally)
  - PBI has Three Novel, Enabling, Patented & Proprietary Pressure-based Platforms: PCT, BaroFold, & UST
  - PCT Platform Breaks Through Bottlenecks to Enable/Accelerate Discovery & QC in Drug Development
  - BaroFold Platform Impacts/Improves Protein Drug Therapeutics through Disaggregation and Refolding
  - UST Platform Makes Highly Stable Nanoemulsions for Multiple Applications, e.g., CBD & Cosmetics Products
  - Significant Worldwide Market Opportunities: PCT (BioPharma \$526B); BaroFold (Drug Processing \$44B); UST (CBD \$44B; Cosmetics \$805B; BioPharma Drug Delivery \$900B; Food and Beverages \$5.65T)
- 

## RECENT & KEY ANNOUNCEMENTS

- January 20, 2021: PBI targets revolution in effectiveness of therapeutics via improved drug delivery and dosing safety; announces collaboration with SinuSys Corp to improve and optimize their lead sinus health product candidate prior to Phase IIb trials.
  - December 17, 2020: Company reports its PCT Platform is at the forefront in generating pivotal findings by diverse COVID-19 research teams in the USA, China, and Europe
  - December 15: Company announces planned presentation on December 17, 2020 at the Life Sciences Investor Forum: <https://www.lifesciencesinvestorforum.com/>
  - December 4: Company Announces that its proposed acquisition partner Cannaworx, Inc. has set a December 2020 launch date for its FDA Registered Immune Booster product
  - November 17: Company Reports Third Quarter 2020 Financial Results – instrument sales increase 68%, total revenue increases 7%, operating loss decreases 23%.
  - November 11: Company was awarded the first U.S. patent for its revolutionary Ultra Shear Technology™ (UST™) platform.
  - October 6: Company achieves critical milestone in revolutionary nanoemulsification technology development; enters production era for commercial system (BaroShear K45) development.
  - August 12: PBI awarded pivotal U.S. patent for novel, high pressure enhanced consumable device. New patent secures and protects PBI's best-selling PCT Sample Preparation Consumable Product, the PCT MicroPestle.
  - June 20: PBI and Leica Microsystems sign worldwide co-marketing alliance: combination of proprietary technologies expected to accelerate cancer R&D with innovative tumor processing workflow.
  - June 11: \$3.5 million initial order for FDA-registered premium hand sanitizer catapults SkinScience Labs, a pending accretive acquisition of PBI, into the multi-billion-dollar hand sanitizer market.
  - June 4: PBI announces first manufacturing build completely sold out for revolutionary UST System for processing hemp-derived cannabinoid oil into stable, water-soluble nanoemulsions.
  - May 28: PBI pending merger partner Cannaworx, Inc. announces launch (mid-July 2020) of novel, FDA-registered immune booster.
  - May 19: PBI pending merger partner Cannaworx, Inc. announces Letter of Intent to Acquire Five Leaf Labs, delivering major expansion of sales and distribution network.
  - May 14: PBI announces launch of FDA-registered hand sanitizer as first product developed through pending merger partners.
  - May 7: Former L'Oréal President Jim Morrison, one of the top brand strategists in the personal care space. worldwide, appointed as CEO to lead Availa Bio upon merger completion.
  - May 5: PBI announces plans to change name to Availa Bio following completion of the Cannaworx and SkinScience Labs merger.
  - April 30: PBI announces plans to acquire SkinScience Labs and their profitable and award-winning Dr. Denese Skin Care and Anti-Aging Lines.
  - April 29: PBI announces plans to acquire Cannaworx, Inc. and their portfolio of innovative consumer products.
  - April 16: PBI and RedShiftBio demonstrate potential of combining proprietary technologies to enable new tool for development and production of biotherapeutics.
  - March 12: PBI announces that it is nearing a complete sellout on its pre-launch offering of game-changing UST Platform for processing CBD Oil into water-soluble nanoemulsions.
  - February 27: PBI launches new era in preparation of water-soluble nanoemulsions for CBD and other valuable oils with opening of UST Demonstration Laboratory.
  - January 30: PBI announced acceleration of UST Platform rollout for water-soluble CBD with planned release of additional BaroShear product – a benchtop, R&D scale, BaroShear 'Mini' instrument.
  - January 24: PBI announced significant new order and near sellout on revolutionary nanoemulsification system for water-soluble CBD oil. Company said that additional orders are expected shortly.
  - January 9, 2020: PBI reported that the number of published scientific papers in 2019 citing the advantages of the Company's PCT Platform remained strong, with over 20 journal articles for the second straight year.
- 

## BOARD OF DIRECTORS

- Mr. Jeffrey N. Peterson, Chairman
- Mr. Kevin A. Pollack, Esq.
- Mr. Vito Mangiardi
- Dr. Mickey Urdea
- Mr. Richard T. Schumacher

1/21/2021